FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced that the European Patent Office has granted European Patent No. EP 3043825 B1, entitled “Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells.” The patent contains 12 claims covering Sox9-based gene therapy compositions using expression vectors to convert fibroblasts into cartilage-producing cells for individuals needing cartilage repair.

The patent can be validated in selected European Patent Convention states, extending protection for this fibroblast-centered cartilage regeneration approach into major European markets and supporting the company’s orthopedics and degenerative disc indications.

Positive

• European patent EP 3043825 B1 granted covering Sox9-based cartilage gene therapy claims
• Geographic IP expansion with validation possible across selected European Patent Convention states
• Supports pipeline for fibroblast-based orthopedics and disc degeneration indications

Negative

• None.

Market reaction after European patent grant: FBLG +5.60% in the Aug 5 session

+5.60% 4.7x vol

23 alerts

+5.60% Session close to close

+26.0% Peak in 25 hr 49 min

$6.91M Market Cap

4.7x Rel. Volume

In the Aug 5 session, FBLG gained 5.60%, reflecting a notable positive market reaction. Argus tracked a peak move of +26.0% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 4.7x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.6% in the session following this news. Historical event 1076355 recorded a 19.22%...

Analysis

The stock moved +5.6% in the session following this news. Historical event 1076355 recorded a 19.22% 24-hour reaction. A strong response could place the patent grant alongside prior conference-related attention, while the active S-3 remains a resale registration rather than company proceeds.

Key Figures

Patents issued and pending: 270+ patents Granted claims: 12 claims European patent: EP 3043825 B1

3 metrics

Patents issued and pending 270+ patents Company description

Granted claims 12 claims European Patent No. EP 3043825 B1

European patent EP 3043825 B1 Patent covering gene therapy for cartilage regeneration

Historical Context

5 past events · Latest: Jul 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 09	Board appointment	Positive	+5.4%	Kathleen Rubins joined the board after prior service on the scientific advisory board.
Jul 07	Manufacturing update	Positive	-3.3%	Third CYWC628 batch completed for the ongoing Phase 1/2 diabetic foot ulcer trial.
Jun 30	Conference participation	Neutral	+19.2%	Management participated in a fireside chat at the H.C. Wainwright cell therapy conference.
Jun 29	Private placement	Negative	+19.2%	The company closed a private placement with upfront proceeds and accompanying warrants.
Jun 26	Private placement	Negative	+12.7%	The company announced an at-the-market private placement with shares and warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news reactions were mostly divergent, with positive moves following financing and conference-related announcements but a decline after manufacturing news.

Key Terms

gene therapy, sox9, expression vectors, chondrocytes, +1 more

5 terms

gene therapy medical

"European Patent No. EP 3043825 B1"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

sox9 medical

"including Sox9, for use in treating individuals in need of cartilage repair"

SOX9 is a gene that makes a protein acting like a master switch for how certain cells develop, especially those that form cartilage and parts of the reproductive system. Investors encounter SOX9 in biotech and healthcare news because changes in the gene or its protein can be targets for drugs, diagnostics, or gene therapies; think of it as a control knob researchers try to understand or adjust when developing treatments.

expression vectors technical

"compositions comprising one or more expression vectors encoding therapeutic polynucleotides"

Expression vectors are engineered DNA or RNA constructs, often carried by harmless viruses or plasmids, that deliver and activate a particular gene inside living cells so the cell makes a chosen protein. Think of them as a delivery vehicle or recipe card that tells cells what protein to produce; investors watch them because the choice of vector affects a therapy's safety profile, manufacturing complexity, regulatory pathway, intellectual property, and commercial scalability.

chondrocytes medical

"producing chondrocytes or cartilage-type cells in the joint"

Specialized cells that make and maintain cartilage, the flexible tissue that cushions joints and shapes parts like the nose and ear. Think of them as the builders and caretakers of a rubbery cushion: they produce the proteins and sugars that form cartilage’s structure and repair. They matter to investors because therapies, drugs, and medical devices targeting cartilage health or regenerative medicine often focus on influencing chondrocyte function or survival.

chondrogenesis medical

"Sox9 is a master regulator of chondrogenesis"

Chondrogenesis is the biological process by which cartilage cells (chondrocytes) form and produce the structural proteins and matrix that make up cartilage. For investors, it matters because therapies, implants, or drugs that promote or mimic chondrogenesis are key to treating joint damage, congenital defects, and some degenerative diseases—think of it as the body’s way of building or repairing the cushioning in joints, which can be a focus of biotech and medical-device investments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting the Company's orthopedics and degenerative disc pathways

HOUSTON, Aug. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office (EPO) has granted the Company's patent entitled "Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells."

The granted patent, European Patent No. EP 3043825 B1, contains 12 claims directed to compositions comprising one or more expression vectors encoding therapeutic polynucleotides, including Sox9, for use in treating individuals in need of cartilage repair. The patent will be validated across selected designated contracting states of the European Patent Convention, extending the Company's protection for this technology into major European markets.

Some of the granted claims include:

• Compositions comprising one or more expression vectors encoding therapeutic polynucleotides that include Sox9, for use in producing chondrocytes or cartilage-type cells in the joint of an individual in need of cartilage repair.
• Delivery of those expression vectors to fibroblast cells, which then differentiate into chondrocytes or cartilage-type cells, either before or after delivery to the joint.
• Use of viral and non-viral vectors for genetic modification.
• Combinations of Sox9 with additional therapeutic genes on a single or multiple vectors.

Cartilage does not meaningfully repair itself, leaving patients with only the therapeutic options of tissue grafting and joint replacement. The granted claims cover an approach that works with the biology already present at the site of injury, instructing fibroblasts to take on a chondrocyte phenotype and produce cartilage matrix components rather than replacing damaged tissue with hardware or donor material. The patent supports FibroBiologics' fibroblast-based approach to cartilage regeneration for orthopedics and disc degeneration indications.

"Cartilage loss sits behind an enormous amount of pain and disability worldwide, and the treatments available today largely manage the consequences rather than rebuild the tissue," said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics. "Securing this patent in Europe extends protection for our cartilage regeneration work into a major market and reinforces a strategy we have followed from the beginning, which is to build a global intellectual property position around the therapeutic potential of fibroblasts."

"Sox9 is a master regulator of chondrogenesis, and the claims recognize the use of this gene to direct fibroblasts toward a cartilage-producing phenotype," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "Cartilage is avascular, aneural, and low in oxygen, which is what has made it so difficult to reach. The granted claims cover the practical elements that allow a gene therapy approach to work in an avascular, low-oxygen cartilage environment."

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company's intellectual property portfolio, the potential indications for FibroBiologics' programs, FibroBiologics' research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-granted-european-patent-covering-gene-therapy-for-the-regeneration-of-cartilage-302843074.html

SOURCE FibroBiologics, Inc.

FAQ

What did FibroBiologics (FBLG) announce on August 5, 2026 about its cartilage gene therapy patent?

FibroBiologics announced that the European Patent Office granted European Patent EP 3043825 B1 covering its cartilage regeneration gene therapy. According to FibroBiologics, the patent includes 12 claims focused on Sox9-based expression vectors to convert fibroblasts into cartilage-producing cells for patients needing cartilage repair.

What technology is protected by FibroBiologics’ new European patent EP 3043825 B1 for FBLG?

The patent protects Sox9-based gene therapy compositions that convert fibroblasts into chondrocytes or cartilage-type cells. According to FibroBiologics, the claims cover expression vectors, viral and non-viral delivery methods, and combinations of Sox9 with other therapeutic genes for cartilage repair applications.

How does FibroBiologics’ Sox9 gene therapy approach aim to regenerate cartilage for FBLG patients?

The approach uses expression vectors encoding Sox9 to reprogram fibroblasts into cartilage-producing chondrocyte-like cells at the injury site. According to FibroBiologics, this strategy works with existing tissue biology instead of relying on hardware, grafts, or donor material for cartilage repair.

In which markets could FibroBiologics’ cartilage gene therapy patent be validated in Europe?

The patent is granted by the European Patent Office and can be validated in selected European Patent Convention contracting states. According to FibroBiologics, this extends intellectual property protection for its cartilage regeneration technology into major European markets relevant to orthopedics and disc degeneration.

How does the new European patent support FibroBiologics’ orthopedics and disc degeneration pipeline for FBLG?

The patent underpins FibroBiologics’ fibroblast-based cartilage regeneration strategy for orthopedic and disc degeneration indications. According to FibroBiologics, the granted claims align with its clinical pathways that leverage fibroblasts and fibroblast-derived materials to address chronic musculoskeletal conditions.

What role does the Sox9 gene play in FibroBiologics’ FBLG cartilage regeneration platform?

Sox9 acts as a master regulator of chondrogenesis, directing cells toward a cartilage-producing phenotype. According to FibroBiologics, the patent claims recognize Sox9’s use to convert fibroblasts into chondrocytes or cartilage-type cells capable of producing cartilage matrix in challenging avascular, low-oxygen environments.